Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CSPI says Bayer nixes selenium claims

This article was originally published in The Tan Sheet

Executive Summary

Bayer discontinues claims in labeling and marketing that linked selenium in its One A Day Men's multivitamins to reduced risk of prostate cancer, according to the Center for Science in the Public Interest. However, CSPI still may pursue the lawsuit it threatened the company with in June because "Bayer adamantly insists that its claims are perfectly legal and refuses to make any commitment not to start making them again," said Stephen Gardner, CSPI's director of litigation, in an Aug. 11 e-mail. A spokeswoman declined to comment on Bayer's future plans for selenium/prostate cancer claims, though the firm previously said it was halting use of the claims in light of new science and FDA's acceptance of extremely limited health claims for selenium (1"The Tan Sheet" July 6, 2009)

You may also be interested in...



CSPI sues Bayer over prostate claims

The Center for Science in the Public Interest makes good on its threat to sue Bayer over claims linking selenium in its One A Day Men's multivitamins to reduced risk of prostate cancer. The 1complaint, filed Sept. 30 in California state court in San Francisco, acknowledges Bayer removed prostate claims from its Web site but says it did not meet other CSPI demands, including recalling products with the claims and agreeing not to make the claims in the future (2"The Tan Sheet" Aug. 17, 2009). CSPI asks the court to find Bayer in violation of the Consumer Legal Remedies Act and the Unfair Competition Law, and seeks relief for itself and its members. In a Sept. 2 letter attached to the complaint, Bayer threatens to sue CSPI for "false, misleading and defamatory" communications about the One A Day products. A Bayer spokeswoman declined to comment on whether the firm will sue

CSPI Calls On FDA To Make Example Of Bayer One A Day Selenium Claims

The Center for Science in the Public Interest says FDA should "flex its muscles" and make an example of Bayer's selenium claims for One A Day Men's multivitamins, just as it did with General Mills' heart health claims for Cheerios

Vaccine Hesitancy May Drive Distribution Priorities For Early COVID-19 Supply

ACIP defers vote on who should be inoculated first until it has data on a specific product, but vaccine acceptance among different groups could be weighed as factor in setting distribution priorities, committee members suggest.

Topics

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel